A Closer Look at 4 Analyst Recommendations For PROCEPT BioRobotics
Portfolio Pulse from Benzinga Insights
Analysts have provided a range of opinions on PROCEPT BioRobotics (NASDAQ:PRCT) over the past quarter, with the majority being bullish. The average 12-month price target has increased by 12.73% to $75.25. Key analysts from Truist Securities, TD Cowen, and Piper Sandler have raised their ratings and price targets for the company. Despite positive revenue growth, the company faces challenges with profitability and return metrics.
July 16, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown increased bullish sentiment towards PROCEPT BioRobotics, raising the average 12-month price target by 12.73% to $75.25. Key analysts from Truist Securities, TD Cowen, and Piper Sandler have raised their ratings and price targets. The company has shown strong revenue growth but faces challenges in profitability and return metrics.
The increase in the average price target and the raised ratings from key analysts indicate a positive short-term outlook for PROCEPT BioRobotics. However, the company's challenges with profitability and return metrics may temper some of the bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100